Status:
COMPLETED
Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion
Lead Sponsor:
Eastern Hepatobiliary Surgery Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
According to radiology imaging, the patients of HCC are divided into two groups(hypovascular tumor group and moderately vascular tumor group). Every group is divided into TACE therapy with balloon cat...
Eligibility Criteria
Inclusion
- sign the written informed consent form provided.
- diagnosed clinically as HCC,need to take TACE.
Exclusion
- have had an allergic reaction following iodine.
- have been in any TACE or radiotherapy or biotherapy within 30 days before the study.
- HCC of diffuse type,failure of hepatic function, chronic illness or disease including failure of heart function, uncontrolled high blood pressure, heart disorders, serious infection, uncontrolled diabetes mellitus.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
352 Patients enrolled
Trial Details
Trial ID
NCT00826384
Start Date
October 1 2008
End Date
December 1 2010
Last Update
April 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eastern hepatobilliary surgery hospital
Shanghai, Shanghai Municipality, China, 200438